Marktanalyse - Diarrhea - Pipeline Review, H1 2017

Global Markets Direct
02.2017
163 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Diarrhea - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea — Pipeline Review, H1 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 15, 2, 21 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diarrhea - Overview 8

Diarrhea - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Diarrhea - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Diarrhea - Companies Involved in Therapeutics Development 28

A. Menarini Industrie Farmaceutiche Riunite Srl 28

Actelion Ltd 28

Aegis Therapeutics LLC 29

Akthelia Pharmaceuticals Ltd 29

Albireo Pharma Inc 30

AmpliPhi Biosciences Corp 31

Anatara Lifesciences Limited 32

Ardelyx Inc 32

Assembly Biosciences Inc 33

AzurRx BioPharma Inc 33

Bharat Biotech International Ltd 34

CinRx Pharma LLC 34

Codagenix Inc 35

Cosmo Pharmaceuticals NV 35

DesignMedix Inc 36

DiscoveryBiomed Inc 36

Genextra Spa 37

GlaxoSmithKline Plc 37

GP Pharm SA 38

Miyarisan Pharmaceutical Company Ltd 38

Mucosis BV 39

Napo Pharmaceuticals Inc 39

Nippon Shinyaku Co Ltd 40

Novartis AG 40

Pfizer Inc 41

Prokarium Ltd 41

Rebiotix Inc 42

Recce Ltd 42

RedHill Biopharma Ltd 43

RxBio Inc 43

Scandinavian Biopharma Holding AB 44

Sigmoid Pharma Ltd 44

Summit Therapeutics Plc 45

Synthetic Biologics Inc 45

Syntiron LLC 46

Tasly Pharmaceutical Group Co Ltd 46

Wuhan Institute of Biological Products Co Ltd 47

Diarrhea - Drug Profiles 48

ABCD-01 - Drug Profile 48

ABIM-101 - Drug Profile 50

AKT-10081 - Drug Profile 51

ASP-7147 - Drug Profile 52

AZX-1101 - Drug Profile 53

Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 54

cadazolid - Drug Profile 55

Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 57

CBM-588 - Drug Profile 59

cholestyramine - Drug Profile 61

crofelemer DR - Drug Profile 62

Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 66

elsiglutide - Drug Profile 67

Escherichia coli vaccine - Drug Profile 69

ETEC vaccine - Drug Profile 70

ETEC vaccine - Drug Profile 71

Etvax - Drug Profile 72

GVXNSD-133 - Drug Profile 74

GXG-8 - Drug Profile 76

ibodutant - Drug Profile 77

IMSUTMR-1501 - Drug Profile 78

infectious diarrhea [serotype H11] vaccine - Drug Profile 79

LJN-452 - Drug Profile 80

obeticholic acid - Drug Profile 81

octreotide acetate - Drug Profile 92

octreotide acetate MAR - Drug Profile 93

ondansetron hydrochloride CR - Drug Profile 94

ORP-101 - Drug Profile 100

Peptide to Activate NHE-3 for Diarrhea - Drug Profile 101

PF-06425090 - Drug Profile 102

prulifloxacin - Drug Profile 104

PZ-7475 - Drug Profile 106

RBX-2660 - Drug Profile 107

RDX-98940 - Drug Profile 110

RECCE-355 - Drug Profile 111

Recombinant Enzyme for Diarrhea - Drug Profile 112

ribaxamase - Drug Profile 113

ridinilazole - Drug Profile 119

rifamycin CR - Drug Profile 125

Rotavac-5C - Drug Profile 128

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 129

Rx-100 - Drug Profile 130

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 132

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 133

Small Molecules for Microbial Infections - Drug Profile 134

Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 135

Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 136

SYN-006 - Drug Profile 137

SYN-007 - Drug Profile 138

Typhetec - Drug Profile 139

Vaccine 1 for Diarrhea - Drug Profile 140

Vaccine 2 for Diarrhea - Drug Profile 141

Vaccine for Traveler's Diarrhea - Drug Profile 142

Vaccine for Traveler's Diarrhea - Drug Profile 143

Yersinia pestis vaccine - Drug Profile 144

Diarrhea - Dormant Projects 145

Diarrhea - Discontinued Products 147

Diarrhea - Product Development Milestones 148

Featured News & Press Releases 148

Appendix 158

Methodology 158

Coverage 158

Secondary Research 158

Primary Research 158

Expert Panel Validation 158

Contact Us 158

Disclaimer 159





List of Tables

Number of Products under Development for Diarrhea, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017

Diarrhea - Pipeline by Actelion Ltd, H1 2017

Diarrhea - Pipeline by Aegis Therapeutics LLC, H1 2017

Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017

Diarrhea - Pipeline by Albireo Pharma Inc, H1 2017

Diarrhea - Pipeline by AmpliPhi Biosciences Corp, H1 2017

Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2017

Diarrhea - Pipeline by Ardelyx Inc, H1 2017

Diarrhea - Pipeline by Assembly Biosciences Inc, H1 2017

Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2017

Diarrhea - Pipeline by Bharat Biotech International Ltd, H1 2017

Diarrhea - Pipeline by CinRx Pharma LLC, H1 2017

Diarrhea - Pipeline by Codagenix Inc, H1 2017

Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2017

Diarrhea - Pipeline by DesignMedix Inc, H1 2017

Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2017

Diarrhea - Pipeline by Genextra Spa, H1 2017

Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2017

Diarrhea - Pipeline by GP Pharm SA, H1 2017

Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017

Diarrhea - Pipeline by Mucosis BV, H1 2017

Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2017

Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Diarrhea - Pipeline by Novartis AG, H1 2017

Diarrhea - Pipeline by Pfizer Inc, H1 2017

Diarrhea - Pipeline by Prokarium Ltd, H1 2017

Diarrhea - Pipeline by Rebiotix Inc, H1 2017

Diarrhea - Pipeline by Recce Ltd, H1 2017

Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2017

Diarrhea - Pipeline by RxBio Inc, H1 2017

Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2017

Diarrhea - Pipeline by Sigmoid Pharma Ltd, H1 2017

Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2017

Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2017

Diarrhea - Pipeline by Syntiron LLC, H1 2017

Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017

Diarrhea - Dormant Projects, H1 2017

Diarrhea - Dormant Projects, H1 2017 (Contd..1), H1 2017

Diarrhea - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Diarrhea, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus